Skip to main content
The Globe and Mail
Support Quality Journalism
The Globe and Mail
First Access to Latest
Investment News
Collection of curated
e-books and guides
Inform your decisions via
Globe Investor Tools
Just$1.99
per week
for first 24 weeks

Enjoy unlimited digital access
Enjoy Unlimited Digital Access
Get full access to globeandmail.com
Just $1.99 per week for the first 24 weeks
Just $1.99 per week for the first 24 weeks
var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(select.open)}function setPanelState(o){dom.root.classList[o?"add":"remove"](select.open),dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){window.requestAnimationFrame(function() {var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))});}pencilInit(".js-sub-pencil",!1); // via darwin-bg var slideIndex = 0; carousel(); function carousel() { var i; var x = document.getElementsByClassName("subs_valueprop"); for (i = 0; i < x.length; i++) { x[i].style.display = "none"; } slideIndex++; if (slideIndex> x.length) { slideIndex = 1; } x[slideIndex - 1].style.display = "block"; setTimeout(carousel, 2500); }
Coronavirus information
Coronavirus information
The Zero Canada Project provides resources to help you make the most of staying home.
Visit the hub

The United States and its top economic allies pledged Monday to more closely share real-time information about the coronavirus and the availability of medical equipment and to support jobs, global trade and investment.

They also vowed to bolster science, research and technology and work to restore public confidence about the pandemic threatening the world’s economy.

President Donald Trump and other members of the Group of Seven, which includes Canada, Germany, Italy, Japan, Britain and France, held a teleconference to co-ordinate responses to the coronavirus and reduce U.S.-European tension over Trump’s travel ban and reports about White House talks with a German company developing a vaccine.

Story continues below advertisement

“We are mobilizing the full range of instruments, including monetary and fiscal measures, as well as targeted actions, to support immediately and as much as necessary the workers, companies and sectors most affected,” they said in a statement.

Trump has had an on-again, off-again relationship with top U.S. allies, but his top economic adviser Larry Kudlow said there was a high degree of co-operation on display during the teleconference.

“They’re not always so agreeable, but they are today,” Kudlow told reporters at the White House. “It’s a wonder to see.”

But the leaders also addressed a controversy involving German company CureVac that rattled top German officials, including Economy Minister Peter Altmaier, who said “Germany is not for sale.”

On Sunday, Germany’s Welt am Sonntag newspaper, citing unidentified German government sources, reported that the former head of CureVac joined Trump’s March meeting with pharmaceutical managers. The report said Trump apparently offered the German firm a large amount of funding to secure its work for the U.S.

The company, which is based in Tuebingen, Germany, and has a site in Boston, on Monday denied reports that the Trump administration was angling to acquire it. In a tweet Monday, the company tweeted: “CureVac has not received from the U.S. government or related entities an offer before, during and since the task force meeting in the White House.”

Shortly after the teleconference, the European Union announced it was providing $89.4 million (80 million euros) of financial support to CureVac to scale up development and production of a vaccine against the coronavirus.

Story continues below advertisement

“We are determined to provide CureVac with the financing it needs to quickly scale up development and production of a vaccine against the coronavirus,” Commission President Ursula von der Leyen said in a statement. “I am proud that we have leading companies like CureVac in the EU. Their home is here. But their vaccines will benefit everyone, in Europe and beyond.”

French President Emmanuel Macron considers that many unilateral decisions taken by countries across the globe are counterproductive in fighting the outbreak. He has sought to mediate tensions that flared last week when the U.S. imposed a travel ban on European countries without consulting them.

“We will co-ordinate research efforts on a vaccine and treatments, and work on economic and financial response,” Macron tweeted.

Related topics

Report an error
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies